Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma

The Liver stiffness measurement hepatocellular carcinoma (LSM‐HCC) score predicts HCC accurately in patients with chronic hepatitis B (CHB).

[1]  V. Wong,et al.  HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. , 2019, Journal of hepatology.

[2]  Yasuhito Tanaka,et al.  Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B , 2018, Alimentary pharmacology & therapeutics.

[3]  J. Kao,et al.  Review article: the prevention of hepatitis B‐related hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.

[4]  V. de Lédinghen,et al.  Noninvasive biomarkers in NAFLD and NASH — current progress and future promise , 2018, Nature Reviews Gastroenterology & Hepatology.

[5]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[6]  V. Wong,et al.  Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. , 2017, Journal of hepatology.

[7]  V. Wong,et al.  Serial combination of non‐invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD , 2017, Alimentary pharmacology & therapeutics.

[8]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[9]  I. Durand-zaleski,et al.  Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States , 2017, Hepatology.

[10]  S. Pol,et al.  The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study , 2016, Alimentary pharmacology & therapeutics.

[11]  H. Møller,et al.  The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis , 2016, Alimentary pharmacology & therapeutics.

[12]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[13]  A. Lok,et al.  Hepatitis B virus infection , 2014, The Lancet.

[14]  G. Lo.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with cirrhosis: Facts or fiction? , 2014, Hepatology.

[15]  V. Wong,et al.  Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. , 2014, Journal of hepatology.

[16]  G. Wong,et al.  Non‐invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B , 2014, Alimentary pharmacology & therapeutics.

[17]  V. Wong,et al.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.

[18]  G. Wong,et al.  Transient elastography: Kill two birds with one stone? , 2013, World journal of hepatology.

[19]  V. Wong,et al.  Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. , 2013, Gastroenterology.

[20]  Grace Lai-Hung Wong,et al.  Update of liver fibrosis and steatosis with transient elastography (Fibroscan) , 2013, Gastroenterology report.

[21]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[22]  Ching-Lung Lai,et al.  Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy , 2013, Hepatology.

[23]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[24]  V. Wong,et al.  Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B , 2010, Alimentary pharmacology & therapeutics.

[25]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[26]  V. Wong,et al.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Wong,et al.  Surrogate end points and long-term outcome in patients with chronic hepatitis B. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  V. Wong,et al.  Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B , 2009, Journal of gastroenterology and hepatology.

[29]  A. Chan,et al.  Alanine aminotransferase‐based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B , 2009, Journal of viral hepatitis.

[30]  Vincent Wai-Sun Wong,et al.  Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  V. Wong,et al.  Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[32]  V. Wong,et al.  Liver stiffness measurement: simplicity is prerequisite for reliability. , 2013, Gastroenterology.

[33]  최은희,et al.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .